Arbutus Corporate Presentation_Jan 13 2025_FINAL-v3.pdf

1、NASDAQ:ABUS January 13,2025Corporate Presentation 2025 Arbutus Biopharma,Inc.Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the U.S.Private Securities Litigation Reform Act of 1995 and Canadian securities laws.All statements that are not histori

2、cal facts are hereby identified as forward-looking statements for this purpose and include,among others,statements relating to:the potential market opportunity for HBV;Arbutus ability to meet a significant unmet medical need;the sufficiency of Arbutus cash and cash equivalents for the anticipated du

3、rations;the expected cost,timing and results of Arbutus clinical development plans and clinical trials,including its clinical collaborations with third parties;the potential for Arbutus product candidates to achieve their desired or anticipated outcomes;Arbutus expectations regarding the timing and

4、clinical development of Arbutus product candidates,including its articulated clinical objectives;the timeline to a combination cure for HBV;Arbutus expectations regarding its technology licensed to third parties;the expected timing and payments associated with strategic and/or licensing agreements;A

5、rbutus expectations with respect to utilizing its ATM program;the patent infringement lawsuits;and other statements relating to Arbutus future operations,future financial performance,future financial condition,prospects or other future events.With respect to the forward-looking statements contained

6、in this presentation,Arbutus has made numerous assumptions regarding,among other things:the timely receipt of expected payments;the effectiveness and timeliness of clinical trials,and the usefulness of the data;the timeliness of regulatory approvals;the continued demand for Arbutus assets;and the st